Furiex Announces Takeda Receives Marketing Authorization for VIPIDIA
Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today confirmed Takeda
Pharmaceutical Company Limited (Takeda)'s announcement that the European
Commission has granted Marketing Authorization (MA) for VIPIDIA™
(alogliptin) for the treatment of Type 2 diabetes patients who are
uncontrolled on existing therapies and for the fixed-dose combinations
VIPDOMET™ (alogliptin and metformin) and INCRESYNC™ (alogliptin and
pioglitazone). The Committee for Medicinal Products for Human Use
(CHMP), of the European Medicines Agency (EMA), issued a positive
opinion for these products on July 26, 2013.
Under its agreement with Takeda, the MA triggers a $10 million milestone
payment to Furiex. Furiex is also eligible to receive tiered royalties
on product sales in the EU and potential sales-based milestones.